Seattle biotech startup AltPep raises $23.1M to tackle Alzheimer’s and related diseases Jan 14, 2021Read Geekwire article: Seattle biotech startup AltPep raises $23.1M to tackle Alzheimer’s and related diseases
AltPep announces that Chad Robins joined AltPep Board of Directors Sep 20, 2020Chad is the co-founder and CEO of Adaptive Biotechnologies, a commercial-stage biotech company in Seattle that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease.
AltPep completes round of initial seed funding Sep 15, 2020AltPep completes round of initial seed funding.
AltPep sets up first lab in Fluke Hall at the University of Washington CoMotion Incubator Sep 15, 2019
Seattle-based life sciences consulting and incubator company, Intutive-X joins AltPep launch Apr 17, 2019
GeekWire—To fight Alzheimer’s disease, Univ. of Washington researchers target plaque-causing proteins Apr 16, 2019View article here.
University of Washington exclusively licenses intellectual property developed in Daggett Lab Apr 16, 2019
Medical News Today—Alzheimer’s: Synthetic protein blocks toxic beta-amyloid Apr 16, 2019View article here.
Genetic Engineering & Biotechnology News—Alzheimer’s Disease Toxicity Halted by Synthetic Peptides Apr 15, 2019View article here.
Research America, Investment in Research Saves Lives and Money Series—Alzheimer’s Fact Sheet Apr 15, 2019View fact sheet here.
Recent Comments